Kiniksa Pharmaceuticals (KNSA)
US Market

Kiniksa Pharmaceuticals (KNSA) Stock Price & Analysis


KNSA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$10.29 - $20.65
Previous Close$17.54
Average Volume (3M)499.78K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$184.99M
Total Debt (Recent Filing)$13.52M
Price to Earnings (P/E)5.4
Oct 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.27
Shares Outstanding70,166,898
10 Day Avg. Volume275,018
30 Day Avg. Volume499,778
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)3.09
Price to Sales (P/S)16.84
Price to Cash Flow (P/CF)-81.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside58.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $10.29 and its highest was $20.65 in the past 12 months.
    What is Kiniksa Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
    Kiniksa Pharmaceuticals’s upcoming earnings report date is Oct 30, 2023 which is in 40 days.
      How were Kiniksa Pharmaceuticals’s earnings last quarter?
      Kiniksa Pharmaceuticals released its earnings results on Jul 25, 2023. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of -$0.142 by $0.352.
        Is Kiniksa Pharmaceuticals overvalued?
        According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Kiniksa Pharmaceuticals pay dividends?
          Kiniksa Pharmaceuticals does not currently pay dividends.
          What is Kiniksa Pharmaceuticals’s EPS estimate?
          Kiniksa Pharmaceuticals’s EPS estimate is -$0.17.
            How many shares outstanding does Kiniksa Pharmaceuticals have?
            Kiniksa Pharmaceuticals has 35,238,255 shares outstanding.
              What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
              Kiniksa Pharmaceuticals reported an EPS of $0.21 in its last earnings report, beating expectations of -$0.142. Following the earnings report the stock price went up 30.388%.
                Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
                Among the largest hedge funds holding Kiniksa Pharmaceuticals’s share is Baker Bros Advisors LP. It holds Kiniksa Pharmaceuticals’s shares valued at 40M.


                  Kiniksa Pharmaceuticals Stock Smart Score

                  The Kiniksa Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Kiniksa Pharmaceuticals

                  Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.


                  Top 5 ETFs holding KNSA

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  iShares Russell 3000 ETF
                  Vanguard U.S. Momentum Factor ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold KNSA. The ETFs are listed according to market value of KNSA within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Mirati Therapeutics
                  Corvus Pharmaceuticals
                  Kura Oncology

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis